Interactive effect of angiotensin II type 1 receptor (AGT1R) polymorphisms and plasma irbesartan concentration on antihypertensive therapeutic responses to irbesartan

Journal of Hypertension

Volumn 29, Issue 5, 2011, Pages 890-895

  Jiang, Shanqun ^a,b   Hsu, Yi Hsiang ^c,d   Venners, Scott A ^e   Zhang, Yan ^b   Xing, Houxun ^b   Wang, Xiaobin ^f   Xu, Xiping ^b,g  

^a ANHUI UNIVERSITY   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e SIMON FRASER UNIVERSITY   (Canada)

^f CHILDREN'S MEMORIAL HOSPITAL   (United States)

^g UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

AGT1R; essential hypertension; irbesartan; polymorphism; response

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; IRBESARTAN;

ADULT; AGED; ARTICLE; CHINESE; DRUG BLOOD LEVEL; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 79954869387     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32834494f6     Document Type: Article

References (30)

1. Jiang S, Mao G, Zhang S, Hong X, Tang G, Li Z, et al. Individual and joint association of alpha1A-adrenergic receptor Arg347Cys polymorphism and plasma irbesartan concentration with blood pressure therapeutic response in Chinese hypertensive subjects. Clin Pharmacol Ther 2005; 78:239-248. (Pubitemid 41254109)
2. Kurland L, Hallberg P, Melhus H, Liljedahl U, Hashemi N, Syvänen AC, et al. The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial. Am J Hypertens 2008; 21:836-839. (Pubitemid 351913624)
3. Hong X, Zhang S, Mao G, Jiang S, Zhang Y, Yu Y, et al. CYP2C93 allelic variant is associated with metabolism of irbesartan in Chinese population. Eur J Clin Pharmacol 2005; 61:627-634.
4. Kurland L, Liljedahl U, Karlsson J, Kahan T, Malmqvist K, Melhus H, et al. Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. Am J Hypertens 2004; 17:8-13. (Pubitemid 38064752)
5. Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman KP, et al., Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) Trial. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens 2001; 19:1783-1787. (Pubitemid 32924944)
6. Zhang S, Mao G, Zhang Y, Tang G, Wen Y, Hong X, et al. Association between human atrial natriuretic peptide Val7Met polymorphism and baseline blood pressure, plasma trough irbesartan concentrations, and the antihypertensive efficacy of irbesartan in rural Chinese patients with essential hypertension. Clin Ther 2005; 27:1774-1784. (Pubitemid 41815228)
7. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996; 334:1649-1654. (Pubitemid 126613653)
8. Croom KF, Curran MP, Goa KL, Perry CM. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. Drugs 2004; 64:999-1028. (Pubitemid 38608479)
9. Gillis JC, Markham A. Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 1997; 54:885-902. (Pubitemid 27526898)
10. Pool JL, Guthrie RM, Littlejohn TW 3rd, Raskin P, Shephard AM, Weber MA, et al. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens 1998; 11 (4 Pt 1): 462-470. (Pubitemid 28231459)
11. Reeves RA, Lin CS, Kassler-Taub K, Pouleur H. Dose-related efficacy of irbesartan for hypertension: an integrated analysis. Hypertension 1998; 31:1311-1316. (Pubitemid 28248833)
12. Ito M, Oliverio MI, Mannon PJ, Best CF, Maeda N, Smithies O, Coffman TM. Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc Natl Acad Sci USA 1995; 92:3521-3525.
13. Crowley SD, Gurley SB, Herrera MJ, Ruiz P, Griffiths R, Kumar AP, et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. ProcNatlAcadSciUSA2006;103:17985-17990. (Pubitemid 44852272)
14. Bonnardeaux A, Davies E, Jeunemaitre X, Fé ry I, Charru A, Clauser E, et al. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 1994; 24:63-69. (Pubitemid 24195405)
15. Kobashi G, Hata A, Ohta K, Yamada H, Kato EH, Minakami H, et al. A1166C variant of angiotensin II type 1 receptor gene is associated with severe hypertension in pregnancy independently of T235 variant of angiotensinogen gene. J Hum Genet 2004; 49:182-186. (Pubitemid 38657566)
16. Wang JL, Li Xue, Hao PP, Feng Xu, Chen YG, Yun Zhang. Angiotensin II type 1 receptor gene A1166C polymorphism and essential hypertension in Chinese: a meta-analysis. J Renin Angiotensin Aldosterone Syst 2010; 11:127-135.
17. Livak KJ. Allelic discrimination using fluorogenic probes and the 50 nuclease assay. Genet Anal 1999; 14:143-149. (Pubitemid 29095371)
18. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002; 70:425-434. (Pubitemid 34112296)
19. Yu H, Lin S, Jin L, Yu Y, Zhong J, Zhang Y, Liu G. Adenine/cytosine1166 polymorphism of the angiotensin II type 1 receptor gene and the antihypertensive response to angiotensin-converting enzyme inhibitors. J Hypertens 2009; 27:2278-2282.
20. Głuszek J, Jankowska K. Is there relationship between the A1166C polymorphism of the angiotensin II receptor AT1 and plasma renin activity, insulin resistance and reduction of blood pressure after angiotensinconverting enzyme inhibitor therapy? Pol Arch Med Wewn 2008; 118:194-200. (Pubitemid 351613059)
21. Suonsyrjä T, Hannila-Handelberg T, Fodstad H, Donner K, Kontula K, Hiltunen TP. Renin-angiotensin system and alpha-adducin gene polymorphisms and their relation to responses to antihypertensive drugs: results from the GENRES study. Am J Hypertens 2009; 22:169-175.
22. Redon J, Luque-Otero M, Martell N, Chaves FJ, POLPRI Investigators. Renin-angiotensin system gene polymorphisms: relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients. Pharmacogenom J 2005; 5:14-20. (Pubitemid 40220612)
23. Konoshita T, Kato N, Fuchs S, Mizuno S, Aoyama C, Motomura M, et al., Genomic Disease Outcome Consortium (G-DOC) Study Investigators. Genetic variant of the renin-angiotensin system and diabetes influences blood pressure response to angiotensin receptor blockers. Diabetes Care 2009; 32:1485-1490.
24. Van den Meiracker AH, Admiraal PJ, Janssen JA, Kroodsma JM, de Ronde WA, Boomsma F, et al. Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension. Hypertension 1995; 25:22-29.
25. Mottl AK, Shoham DA, North KE. Angiotensin II type 1 receptor polymorphisms and susceptibility to hypertension: a HuGE review. Genet Med 2008; 10:560-574.
26. Spiering W, Kroon AA, Fuss-Lejeune MM, Daemen MJ, de Leeuw PW. Angiotensin II sensitivity is associated with the angiotensin II type 1 receptor A(1166)C polymorphism in essential hypertensives on a high sodium diet. Hypertension 2000; 36:411-416.
27. Martin MM, Buckenberger JA, Jiang J, Malana GE, Nuovo GJ, Chotani M, et al. The human angiotensin II type 1 receptor \+1166A/C polymorphism attenuates microrna-155 binding. J Biol Chem 2007; 282:24262-24269. (Pubitemid 47328062)
28. de Denus S, Zakrzewski-Jakubiak M, Dubé MP, Bé langer F, Lepage S, Leblanc MH, et al. Effects of AGTR1 A1166C gene polymorphism in patients with heart failure treated with candesartan. Ann Pharmacother 2008; 42:925-932.
29. Lim HS, Cho JY, Oh DS, Chung JY, Hong KS, Bae KS, et al. Angiotensin II type 1 receptor 1166A/C polymorphism in association with blood pressure response to exogenous angiotensin II. Eur J Clin Pharmacol 2007; 63:17-26.
30. Sookoian S, Castaño G, Garća SI, Viudez P, Gonzá lez C, Pirola CJ. A1166C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension. Am J Gastroenterol 2005; 100:636-642. (Pubitemid 40487564)